WO2003080671A1 - Anticorps monoclonaux anti-rank et compostion pharmaceutique contenant ceux-ci - Google Patents

Anticorps monoclonaux anti-rank et compostion pharmaceutique contenant ceux-ci Download PDF

Info

Publication number
WO2003080671A1
WO2003080671A1 PCT/KR2003/000553 KR0300553W WO03080671A1 WO 2003080671 A1 WO2003080671 A1 WO 2003080671A1 KR 0300553 W KR0300553 W KR 0300553W WO 03080671 A1 WO03080671 A1 WO 03080671A1
Authority
WO
WIPO (PCT)
Prior art keywords
rank
cells
monoclonal antibody
antibody
differentiation
Prior art date
Application number
PCT/KR2003/000553
Other languages
English (en)
Inventor
Zang-Hee Lee
Hong-Hee Kim
Original Assignee
Komed Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Komed Co., Ltd. filed Critical Komed Co., Ltd.
Priority to AU2003210054A priority Critical patent/AU2003210054A1/en
Publication of WO2003080671A1 publication Critical patent/WO2003080671A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Definitions

  • the present invention relates to an anti-receptor activator of nuclear factor KB (RANK) monoclonal antibody and a pharmaceutical composition comprising the monoclonal antibody. More particularly, the present invention relates to an anti-RANK monoclonal antibody capable of selectively recognizing RANK and inhibiting osteoclastic differentiation, a hybridoma producing the monoclonal antibody, and a pharmaceutical composition for treating bone metabolism disorders by inhibiting osteoclastic differentiation, comprising the monoclonal antibody or its fragments. Also, the present invention is concerned with a method for screening inhibitors of osteoclast differentiation with the use of the monoclonal antibody.
  • RANK nuclear factor KB
  • Bone metabolism functions reside primarily with two cells: osteoblasts_responsible for the synthesis of bone and osteoclasts involved in cell resorption. Osteoblasts and osteoclasts differ in their cellular origins and maturation process. While osteoblasts are generated from mesenchymal cells, osteoclasts originate from mesenchyte/macrophage precursor cells. Imbalance between activities of osteoblasts and osteoclasts leads to changes of various hormones, inflammation factors, and growth factors, resulting in disorders of the skeletal system, for example, bone loss (osteoporosis) or bone resorption (osteopetrosis).
  • menopausal osteoporosis bone metastatic lesion caused by the migration of tumors such as breast cancer or prostatic cancer to bone
  • primary bone tumor e.g., multiple myeloma
  • melanoma a primary bone tumor
  • bone resorption which is due mainly to the activation of osteoclast differentiation and the enhancement of osteoclastic functions.
  • Osteoclasts are known to stem from hemapoietic stem cells of monocyte/macrophage lineage and to be differentiated under the influence of various hormones, growth regulation factors, cytokines and etc., but this mechanism remains unclear. It is also known that marrow cells, peripheral blood monocytes, and spleen cells, when they are mixed in vivo, can all be differentiated to osteoclasts. Representative of agents accelerating osteoclast differentiation is l ⁇ , 25-dihydroxyvitamin D 3 . According to a report, factors originating from basal cells/osteoblasts are essential to the induction of the precursor cell fusion for the formation of osteoclast-like multmucleated cells.
  • Receptor activator of nuclear factor KB is a member of the tumor necrosis factor receptor (TNFR) superfamily.
  • TNFR tumor necrosis factor receptor
  • the TNFR superfamily comprises cell-surface receptors including type 1 and 2 TNF receptors (TNFRl and TNFR2), Fas, CD27, 4-1BB and CD30. Signaling of TNFR is triggered by ligand-receptor binding (Baker and Reddy, Oncogene, 17, 3261-3270 (1998)).
  • RANK which is a newly discovered member of the TNFR superfamily, identified as a dentritic cell membrane protein, stimulates T-cell proliferation and dentritic cell functions (Anderson et al., Nature, 390,175-179(1997); Green and Flavell, J. Exp. Med., 189, 1017-1020 (1999)).
  • the cell membrane protein is also reported to be involved in bone metabolism (Nakagawa et al, Biochem. Biophys. Res. Commun., 253, 395-400 (1998)).
  • RANK-deficient mice are characterized by profound osteopetrosis resulting from an apparent block in osteoclast differentiation, with failure of tooth eruption, and defective lymph node formation (Li et al., Proc. Natl. Acad. Sci. USA, 97, 1566-1571(2000): Dougall et al., Genes Dev. 13, 2412-2424 (1999).
  • an anti- RANK monoclonal antibody or its fragments capable of selectively recognizing RANK and inhibiting osteoclastic differentiation.
  • a method for producing an anti-RANK monoclonal antibody in accordance with another aspect of the present invention, there is provided a method for producing an anti-RANK monoclonal antibody.
  • a hybridoma in accordance with a further aspect of the present invention, there is provided a hybridoma, producing the anti-RANK monoclonal antibody.
  • kits for diagnosing bone metabolism disorders comprising the monoclonal antibody or its fragments.
  • a method for diagnosing bone metabolism disorders comprising the steps of: bringing a biological sample of an animal into contact with the antibody or its fragments; and (b) measuring the RANK expression of the biological sample and comparing with the RANK expression of a control obtained from a healthy animal.
  • a pharmaceutical composition for treating bone metabolism disorders by inhibiting osteoclastic differentiation comprising the monoclonal antibody or its fragments in a therapeutically or prophylactically effective amount, and a pharmaceutically acceptable carrier.
  • a method for screening inhibitors of osteoclast differentiation comprising the steps of: treating an osteoclast differentiation model with a candidate inhibitor; and (b) bringing the osteoclast differentiation model into contact with the antibody or its fragments and quantitatively analyzing RANK expression to determine whether the candidate inhibitor is an inhibitor of osteoclast differentiation as defined by a decrease in RANK expression.
  • Fig. 1 is a schematic diagram showing the construction of the recombinant vector pGEX4T-l:RANK.
  • Fig. 2 shows an electrophoresis result of the recombinant GST-RANK fusion protein.
  • Fig. 3 shows immunofluorescence assay results demonstrating that the monoclonal antibody of the present invention specifically recognizes the RANK expressed in pig vascular endothelial cells (A), HUVEC(human umbilical vein endothelial cell) (B), differentiated osteoclasts (C), and differentiated RAW264.7 cells (D).
  • Fig. 4 shows Western blotting results demonstrating that the monoclonal antibody of the present invention specifically recognizes the RANK expressed in human embryonic kidney 293T (HEK293T) cells.
  • Fig. 5 shows FACS analysis results demonstrating that the monoclonal antibody of the present invention specifically recognizes the RANK expressed in osteoclast-like cells.
  • Figs. 6A-6C are histograms showing the quantitative analysis for the inhibition of osteoclastic differentiation by use of TRAP dyeing method.
  • Fig. 7 is a schematic diagram illustrating the osteoclastic differentiation processes and a method for screening inhibitors of osteoclastic differentiation by use of the monoclonal antibody of the present invention, with resort to HTS (high throughput screening).
  • an anti-RANK monoclonal antibody and its fragments with activity to recognize RANK selectively and inhibit the differentiation of osteoclasts are disclosed.
  • Monoclonal antibodies are proteins which can recognize specific sites of an antigen and bind specifically to the sites. Monoclonal antibodies do not inhibit the activity of antigens without binding specifically to specific sites of antigens. Thus, not all monoclonal antibodies produced against an antigen inhibit the activity of the antigen. Although it is possible to produce monoclonal antibodies capable of recognizing RANK involved in signal transduction, the variety of the antigenic sites of RANK makes it difficult to make monoclonal antibodies which selectively inhibit a desired physiological activity. No monoclonal antibody has been found which acts as an antagonist which inhibits the differentiation of osteoclasts.
  • antibody fragments refers to specific parts of an antibody, which are able to bind to a target antigen, e. g. RANK or its specific sites in this invention.
  • the antibody fragments comprise fragments F(ab')2, Fab, Fab' and Fv.
  • these fragments can be produced with resort to DNA recombinant technology or by digesting the antibody protein with papain or pepsin (CURRENT PROTOCOLS IN IMMUNOLOGY, John Wiley and Sons Coliganet et al., Eds (1991-1992)).
  • the monoclonal antibody fabricated according to the present invention is proved capable of selectively recognizing RANK expressed in tissues and cells as measured by immunofluorescence assay, Western blotting, and fluorescence-activated cell sorter (FACS) (Example 6 to 8). Also, research on the effect of the monoclonal antibody of the present invention on an osteoclast differentiation system has been done. Relative numbers of differentiating osteoclasts are much lower when the system is treated with the monoclonal antibody than when not treated (Example 9).
  • RANK The TNFR superfamily member, RANK, is expressed in epithelial cells, osteoclast precursors, B-cells, and activated T-cells. Having 20-40 % homology in amino acid sequence with other TNFR superfamily members, RANK is a 616-amino acid protein of which the extracellular domain comprises cysteine residues (Anderson et al., Nature 390, 175-179 (1997)).
  • RANKL Activated by association with the ligand RANKL (also named ODF (osteoclast differentiation factor), OPGL (osteoprotegerin ligand), or TRNACE (TNF-related activation induced cytokine)
  • RANKL also named ODF (osteoclast differentiation factor), OPGL (osteoprotegerin ligand), or TRNACE (TNF-related activation induced cytokine)
  • ODF osteoclast differentiation factor
  • OPGL osteoprotegerin ligand
  • TRNACE TNF-related activation induced cytokine
  • the signal transduction pathway of RANK is so complicated that its full processes have not yet been discovered completely. According to literature, the association of RANK with its ligand initiates the signal transduction pathway.
  • the cytoplasmic domain of the RANK-ligand composite recruits TRAF proteins, especially TRAF6, and adaptors such as c- src, and then the TRAF6 activates NF- ⁇ B and JNK(c-Jun N-terminal kinase) which are essential to the formation and activation of osteoclasts (Darnay et al., JBC 273, 20551-20555 (1998)).
  • TRAF6 interacts with c-src to activate Akt/PKB, a serine/threonine kinase which plays a crucial role in anti-apoptosis signal transduction and cytoskeletal system rearragement (Wong et al., Mol. Cell 4,1041-1049 (1999)).
  • mice deficient in NF- ⁇ Bl/NF- ⁇ B2, c-fos, TRAF6 and c-src in which osteoclasts are destroyed or functionally retarded Iotsova et al., Nat Med, 3, 1285-1289 (1998); Grigoriadis et al., Science 266, 443-448 (1994); Lomaga et al., Gene Dev 13, 1015- 1024 (1999); Soriano et al, Cell 64, 693-702 (1991)).
  • the monoclonal antibody of the present invention can be produced by using RANK as an immunogen to immunize animals, fusing splenocytes of the immunized animals with myeloma cells to produce hybridomas, screening the hybridomas to identify those which produce anti-RANK monoclonal antibodies able to selectively recognize RANK and simultaneously inhibit osteoclast differentiation, culturing the screened hybridoma, and isolating the antibodies from the hybridoma culture.
  • the monoclonal antibody of the present invention can be further produced by injecting into animals the hybridoma which selectively recognize RANK and inhibit osteoclast differentiation simultaneously, recovering abdominal dropsy from the animals after a period of time, and isolating the antibodies from the abdominal dropsy.
  • Available as a useful immunogen is a natural RANK protein or a gene-recombinant
  • RANK protein Preferably, gene-recombinant RANK is used. More preferable is a recombinant fusion protein in which RANK is fused with GST (glutathione S-transferase).
  • the most preferable immunogen is a fusion protein in which the extracellular domain (amino acid Nos. 37-206) of RANK is fused with GST.
  • a 45 kD RANK-GST fusion protein is used (Examples 1 to 3).
  • Gene-recombinant RANK can be obtained by preparing cDNA by use of a known base sequence in accordance with a protocol well-known to the art, inserting the cDNA into an expression vector, expressing the vector in a host cell, and isolating the desired protein.
  • expression vectors for eucaryotic or prokaryotic cell hosts may be used as expression vectors.
  • expression control sequences may be adopted from SV40, bovine papilloma virus, adenovirus, adeno-associated virus, cytomegalovirus, or retrovirus.
  • bacterial plasmids such as pET, pRSET, pBluescript, pGEX2T, pUC, col El, pCRl, pBR322, pMB9 and their derivatives, phage DNA exemplified by phage lamda derivatives such as ⁇ gtlO, ⁇ gtl l and NM989, and other DNA phage such as Ml 3 and filament single strand DNA phage may be used.
  • a recombinant expression vector named pGEX4T-l:RANK, is prepared.
  • Host cells useful for the production of the recombinant RANK may be prokaryotic or eucaryotic. Actually, hosts with high efficiency in transformation and expression are selected. Effective prokaryotic and eukaryotic hosts may be exemplified by E. coli, pseudomonas, bacilli, streptomyces, and fungi, with preference to E. coli.
  • Proteins expressed in the hosts can be isolated and purified from cultures by use of various conventional methods, for example, normal or reverse phase liquid chromatography such as HPLC and FPLC; affinity chromatography (inorganic ligands or monoclonal antibodies); size exclusion chromatography; immobilized metal chelate chromatography; and gel electrophoresis.
  • normal or reverse phase liquid chromatography such as HPLC and FPLC
  • affinity chromatography inorganic ligands or monoclonal antibodies
  • size exclusion chromatography size exclusion chromatography
  • immobilized metal chelate chromatography immobilized metal chelate chromatography
  • gel electrophoresis e.
  • affinity chromatography inorganic ligands or monoclonal antibodies
  • the antigen may be administered mfraabdominally, intravenously, intramuscularly, intraretinally, or subcutaneously. If necessary, various techniques may be adopted for boosting the immune response generated by proteins and providing greater antibody reactivity. For instance, the antigenic protein of the present invention may be used in combination with complete or incomplete Freund adjuvant to increase the immunity.
  • the immunization regimen is performed by administering the antigen 2 to 10 times and preferably 2 to 5 times at regular intervals over days to weeks and preferably one to three weeks.
  • Two to five days after the final round of immunization antibody-producing cells can be obtained from the immunized animals.
  • Examples of antibody-producing cells comprise splenocytes, lymphocytes, thymocytes, and peripheral blood cells with preference to splenocytes.
  • the antigen is administered at a dose of 0.0-1,000 ⁇ g and preferably 1-300 ⁇ g per mouse.
  • the antibody-producing cells obtained above are fused with myeloma cells in accordance with a known technique, e.g., Koehler-Milstein method.
  • Myeloma cells suitable to this end are mouse cell line strains, exemplified by p3/x63-Ag8, p3-Ul, NS-1,MPC-11, SP-2/0, FO, P3x63Ag8, V653 and S194.
  • the rat cell line R-210 may be also used.
  • the fused clones are cultured, followed by selecting ones which selectively recognize RANK.
  • the selection of the mono-clones selectively recognizing RANK may resort to immunochemistry, as well known in the art.
  • immunochemical techniques include radio immuno assay (RIA), enzyme-linked immunosorbent assay (ELISA), immunofluorescence, Western blotting, and fluorescence-activated cell sorter (FACS), to which the present invention is not limited.
  • RIA radio immuno assay
  • ELISA enzyme-linked immunosorbent assay
  • FACS fluorescence-activated cell sorter
  • ELISA fluorescence-activated cell sorter
  • the hybridomas producing the RANK-recognizable antibodies are selected the clones which show the activity of inhibiting osteoclast differentiation. This selection can be achieved by treating a model system for osteoclast differentiation with the RANK-recognizing hybridoma culture and quantifying the expression of RANK to detect hybridomas which reduce the expression of RANK.
  • osteoclast differentiation potentially differentiable cells are induced to differentiate to osteoclasts by treatment with differentiation factors.
  • Myelocytes, peripheral blood monocytes, and splenocytes are the cells which are potentially differentiated to osteoclasts. All of them can be differentiated to osteoclast in vitro.
  • RANKL also called ODF
  • mouse osteoclast or RAW264.7 cells are cultured in the presence of
  • ODF to induce the differentiation of osteoclasts. Since hemoto stem cells of bone marrow are differentiated to osteoclasts with the help of osteoblast/basal cells, co-culture systems, e. g., myelocyte/osteoblast, and splenocytes/osteoblast may be used as the osteoclast differentiation model system in accordance with a specific embodiment of the present invention.
  • co-culture systems e. g., myelocyte/osteoblast, and splenocytes/osteoblast may be used as the osteoclast differentiation model system in accordance with a specific embodiment of the present invention.
  • the hybridoma of the present invention which shows dual functions of selectively recognizing RANK and inhibiting osteoclast differentiation, is deposited with KCTC (Korean Collection for Type Cultures) under accession number KCTC 10192BP on Feb. 27, 2002.
  • the hybridoma can be subcultured according to conventional methods and cryopreserved.
  • the hybridoma can be cultured by conventional method to recover the culture or injected into the abdominal cavity to recover ascite.
  • Antibodies contained in the culture or the ascite can be purified by use of conventional purification techniques such as dialysis, ion exchange and gel filtration chromatography, affinity column chromatography, etc.
  • protein A sepharose affinity chromatography may be used for the purification of the antibodies from the culture or abdominal dropsy.
  • the present invention pertains to a kit for diagnosing bone metabolism disorders by taking advantage of the anti-RANK monoclonal antibody or its fragments.
  • the diagnosis kit of the present invention comprises the monoclonal antibody against RANK or its fragment in addition to reagents useful for lmmuno-assay.
  • the immuno-assay reagents they are exemplified by a suitable carrier, a marker generating a detectable signal, a solubihzer, and a detergent.
  • a marker is an enzyme
  • a substrate with which the activity of the enzyme can be measured, and a reaction quencher may be further used.
  • the carrier include soluble carriers such as physiologically acceptable buffers well known to the art (e. g. PBS), and insoluble carriers such as polystyrene, polyethylene, polypropylene, polyester, polyacrylonitrile, fluorine resin, crosslinked dextran, polysaccharide, magnetic particles (metal-coated latex), paper, glass, metals, agarose and combinations thereof.
  • physiologically acceptable buffers well known to the art
  • insoluble carriers such as polystyrene, polyethylene, polypropylene, polyester, polyacrylonitrile, fluorine resin, crosslinked dextran, polysaccharide, magnetic particles (metal-coated latex), paper, glass, metals, agarose and combinations thereof.
  • Enzymes, fluorescent materials, luminescent materials, and radioactive materials can be used as the markers which can generate detectable signals.
  • Peroxidase, alkaline phosphatase, ⁇ -D-galactosidase, glucose oxidase, glucose oxidase, malate dehydrogenase, glucose-6-phosphate dehydrogenase, and invertase fall into the range of the markers useful in the present invention.
  • Fluoric acid isothiocyanate and picoviliprotein are useful as the fluorescent materials.
  • Isolucinol or lucigenin is an example of the luminescent materials. Being radioactive, I 131 , C 14 and H 3 also can be used as markers. However, any material, if it be applied to immuno-assay, can be used, instead of the above-illustrated materials.
  • bone metabolism disorders means disorders caused by an increase in osteoclast differentiation and an enhancement of osteoclast function on the basis of an increase in RANK expression.
  • bone metastatic lesion caused by the migration of tumors such as breast cancer cells or prostatic carcinoma cells to bone, primary bone tumor (e.g., multiple myeloma), and melanoma fall into the category of the bone metabolism disorders.
  • the present invention pertains to a method for diagnosing bone metabolism disorders, comprising the steps of (a) bringing a biological specimen of an animal into contact with the antibody of the present invention or its fragments and (b) measuring the RANK expression of the specimen and comparing with the RANK expression of a control obtained from a healthy animal.
  • Tissues, cells, whole blood, phlegm, serum, plasma, saliva, cerebrospinal fluid, and urine may be the biological specimen.
  • the bone metabolism disorders mentioned in the diagnosis method are as defined above. Quantification of the RANK expression by use of the antibody of the present invention or its fragments may resort to immunochemical methods well known in this art.
  • Illustrative and non-limiting examples include RIA, ELISA, immunofluorescence, Western blotting, and FACS.
  • an immunofluorescence method is conducted (Example 6), in which vascular endothelial tissues, vascular endothelial cells and osteoclasts are brought into contact with a monoclonal antibody conjugated with a fluorescent marker and then observed under a fluorescent microscope to detect RANK expression.
  • Western blotting is conducted to specifically detect RANK proteins expressed in cells (Example 7), in which cells transformed with a vector are cultured to overexpress RANK and treated with monoclonal antibodies of the present invention.
  • FACS Fluorescence Activated Cell Sorting
  • the present invention pertains to a pharmaceutical composition for treating bone metabolism disorders, which is characterized by the activity of inhibiting osteoclast differentiation, comprising the monoclonal antibody of the present invention or its fragments in a therapeutically or prophylactically effective amount, and a pharmaceutically acceptable carrier.
  • a pharmaceutically acceptable carrier comprising pharmaceutically acceptable carriers, adjuvant, and vehicles, which are all generically called “pharmaceutically acceptable carriers”.
  • the pharmaceutically acceptable carriers suitable for the pharmaceutical composition, to which the scope of the present invention is not limited include alumina, aluminum stearate, recitin, serum proteins (e.
  • g., human serum albumin buffers (various phosphates, glycin, sorbic acid, potassium sorbate, partial glyceride mixture of saturated vegetable fatty acid), water, salts or electrolytes (e. g., protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride and zinc salts), viscous silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substrates, polyethylene glycol, sodium carboxymethyl cellulose, polyarylate, wax, polyethylene-polyoxypropylene-block polymer, polyethylene glycol, and lanolin.
  • buffers variant phosphates, glycin, sorbic acid, potassium sorbate, partial glyceride mixture of saturated vegetable fatty acid
  • water salts or electrolytes (e. g., protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride and zinc salts), vis
  • Administration for the pharmaceutical composition of the present invention may be conducted locally or systematically via oral and parenteral routes, of which the illustrative but non-limiting examples include intravenous, intramuscular, intraarterial, intramedullary, intradural, intracardiac, transcutaneous, hypodermic, intraabdominal, intranasal, intraintestinal, sublingual, and intrarectal administration.
  • oral and parenteral routes include intravenous, intramuscular, intraarterial, intramedullary, intradural, intracardiac, transcutaneous, hypodermic, intraabdominal, intranasal, intraintestinal, sublingual, and intrarectal administration.
  • terapéuticaally effective dose means an amount suitable to treat the disorders, ranging from 50 to 500 mg per kg of patient per day.
  • prophylactically effective dose means an amount suitable for the prevention of the disorders, ranging from about 1 to 50 mg per kg of the patient per day.
  • the present invention pertains to a method for screening inhibitors of osteoclast differentiation, comprising the steps of (a) treating an osteoclast differentiation model with inhibitor candidates of osteoclast differentiation and (b) bringing the osteoclast differentiation model into contact with an antibody of the present invention or its fragment and quantifying RANK expression to determine whether the candidates act as inhibitors.
  • a method for screening inhibitors of osteoclast differentiation comprising the steps of (a) treating an osteoclast differentiation model with a candidate with resort to HTS (high throughput screening) and (b) bringing the osteoclast differentiation model into contact with an antibody of the present invention or its fragment and quantitatively analyzing RANK expression to determine the candidate as an inhibitor of osteoclast differentiation in the case of a decrease in RANK expression.
  • the osteoclast differentiation model used for screening inhibitors of osteoclast differentiation is a differentiation induction system.
  • Cells differentiable to osteoclasts comprise myelocytes, mononucleates of peripheral blood, and splenocytes. They can all be differentiated to osteoclasts in vitro.
  • RANKL may be used as a differentiating factor, as explained above, hi a specific embodiment, mouse osteoclast or RAW264.7 cells are cultured in the presence of ODF to induce the differentiation to osteoclasts.
  • a co-culture system of myelocytes and osteoblasts may be used as the osteoclast differentiation model system in accordance with a specific embodiment of the present invention.
  • Quantitative analysis of the RANK expression using the monoclonal antibody of the present invention or its fragment may resort to immunochemical techniques, as described above.
  • HTS is a potential method by which a number of candidate materials can be tested concurrently and screened for their biological activities simultaneously or almost simultaneously.
  • the differentiation of osteoclasts is induced in 48-, 96- or 192-well microtiter plates to which a number of candidate inhibitors are then added, followed by bringing the cells into contact with the antibody of the present invention or its fragment to measure the expression of RANK (Fig. 7).
  • a number of candidate inhibitors are then added, followed by bringing the cells into contact with the antibody of the present invention or its fragment to measure the expression of RANK (Fig. 7).
  • Fig. 7 For example, as many as 96 independent experiments can be simultaneously conducted on a single plastic plate of 8x12 cm size comprising 96 wells. Typically, each well requires an assay volume ranging from 50 to 500 ⁇ l.
  • various equipments such as meters, tools, pipettes, robots, plate washers, plate readers, which are all commercially available, are needed to suit 96-well formats to a wide homogen
  • a RANK-GST fusion protein in which a recombinant RANK was fused with GST was prepared as an antigen for producing anti-RANK monoclonal antibodies.
  • RANK'S extracellular domain (amino acid residue No. 37 to No. 206) was amplified by PCR using a set of the following primers in order to prepare cDNA of RANK.
  • the mixture was first heated at 95 °C for 15 min and subjected to PCR in which a PCR cycle consisting of a denaturation at 94 °C for 1 in, an annealing step at 55 °C for 1 min and an extension step at
  • Primer 1 TR8-GF:5'-CGGATCCGAGAAGCATTATGAGCAT-3'(sense) (Seq. 1)
  • Primer 2 TR8-GR: 5 '-CGAATTCTTCATTTGGTGGTTTTCT-3 "(antisense) (Seq.2)
  • the amplified cDNA of RANK was subcloned into pG ⁇ X4T-l (Pharmacia) at a site digested with the same enzymes to construct the recombinant vector pGEX4T-l:RANK (Fig. 1).
  • E. coli DH5 ⁇ was transformed with the recombinant vector pGEX4T-l:RANK and cultured in an LB medium (tryptone lOg/L, yeast extract 5g/L, NaCl 5g/L) for 16 hours at 37 °C.
  • LB medium tryptone lOg/L, yeast extract 5g/L, NaCl 5g/L
  • Cells in dense suspension were diluted with a fresh LB medium in the ratio 20:1 and cultured for 2 hours at 37 °C.
  • IPTG isopropyl-1- ⁇ -D-thiogalactopyranoside
  • Cells after being withdrawn from the culture, were suspended in a dissolving buffer (50 mM Tris-Cl, 100 mM NaCl, 0.1 % Triton X-100, 0.01 % 2- mercaptomethanol, 0.5 mM EDTA, 0.2 mM PMSF) and disrupted by sonication.
  • the cell homogenate thus obtained was centrifuged at 12,000 rpm at 4 °C for 30 min, and the supernatant was decanted and mixed with Sepharose 4B beads (Pharmacia) for 2 hours at 4 °C to adsorb the fusion protein to the beads. Re-centrifugation at 12,000 rpm for 30 min at 4 °C was performed to isolate the beads.
  • These beads were filled in a column through which an eluent (50 mM Tris-Cl, 50 mM glutathione, pH 7.0) was then passed to elute the RANK-GST fusion protein only.
  • Example 1-2 The eluate obtained in Example 1-2 was reacted in a protein quantification system (Bio-Rad), and the amount of the fusion protein was determined by measuring absorbance at
  • Quantitative analysis of the size of the RANK-GST fusion protein was achieved by electrophoresis, with resort to a vertical electrophoresis apparatus (Bio-Rad). After being loaded on an SDS-polyacrylamide gel (12 %), the eluate was electrophoresed at 80 V. For comparison, a low molecular weight calibration kit (Pharmacia), which served as a marker, was also run on the same gel. After electrophoresis, the gel was dyed with Coomassie brilliant blue R-250 to visualize the proteins run on the gel.
  • the RANK-GST fusion protein was determined to be about 45 kD in size as shown in Fig. 2.
  • Sera obtained form the blood samples were measured for antibody titer, with resort to ELISA using the RANK-GST fusion protein as an antigen.
  • the RANK-GST fusion protein was added in an amount of 100 ⁇ l to each well of 96-well plates and incubated for 1 hour at room temperature with agitation. After washing the wells with phosphate buffer three times, 200 ⁇ l of bovine serum albumin was added to give a final concentration of 1 mg/ml. Washing with phosphate buffer three times made the plates suitable for ELISA. The sera taken from immunized mice were added to each well of the plates, incubated for 1 hour at room temperature with agitation, and washed with phosphate buffer three times.
  • splenocytes were removed from the mice and fused with the myeloma cell line SP2/0(ATCC CRL-581).
  • the spleen was removed aseptically from immunized mice and only cellular components were isolated in a Dulbecco's Modified Eagle Medium (DMEM, Gibco BRL).
  • DMEM Dulbecco's Modified Eagle Medium
  • the splenocytes thus obtained were mixed in the ratio of 1:1 with SP2/0 cells and addition of polyethylene glycol (PEG) facilitated fusion between them.
  • PEG polyethylene glycol
  • To the fused cells was added an HAT medium (Gibco BRL).
  • the clones obtained in Example 3 were cultured and analyzed by ELISA to select positive single clones.
  • the clones obtained in Example 3 were inoculated on 96-well culture plates in such a manner that 10, 5 or 0.5 cells were contained in each well, followed by incubation at 37 °C. HAT medium was used and refreshed every three days.
  • BBL1-2 and BBL1-3 were deposited with KCTC (Korean Collection for Type Cultures) with accession No. KCTC 10192BP on Feb. 27, 2002.
  • the hybridoma of Example 4 was intraabdominally injected into mice to give ascite containing a high concentration of monoclonal antibodies.
  • 0.5 ml of incomplete Freund's adjuvant (Gibco BRL) was intraabdominally injected into Balb/c mice, followed by the mfraabdominal injection with 2x10 7 hybridoma cells, three days later. After two weeks, ascite filled in the abdominal cavity was sampled by use of a syringe lest the samples be contaminated with blood.
  • vascular endothelial tissues, vascular endothelial cells and osteoclasts were reacted with fluorolabeled monoclonal antibodies and analyzed with resort to immunofluorescence assay.
  • osteoclasts used were pig vascular endothelial tissue and HUVEC (human umbilical vascular endothelial cell).
  • HUVEC human umbilical vascular endothelial cell
  • they were osteoclasts that were differentiated in mice and from RAW264.7 cells (ATCC number: TIB-71, Strain: BALB/c, Tissue: Abelson murine leukemia virus-induced tumor; Macrophage; monocyte).
  • Osteoclasts differentiated in mice were obtained as follows.
  • a mouse BALB/c (5 to 6 weeks old) was sacrificed and sufficiently soaked in 70% ethanol. Tibia and femur were separated from the body by use of scissors and a pincette.
  • tibia and femur tissues and muscles were removed by use of a pincette in HBSS containing 3x antibiotic.
  • the tibia and femur were immersed in a fresh 3x HBSS.
  • the bones were cut at their both ends, and ⁇ -MEM was injected into the bones with a 1ml syringe to completely extract bone marrow cells which were then suspended well.
  • the cell suspension was centrifuged for 3 min at 1600 rpm. After removing the supernatant, the cell pellet was re-suspended and added with 20 ml of a buffer for removing red blood cells. The suspension was let to stand for 1 to 2 min.
  • osteoclasts were inoculated at a density of lxl 0 6 cells in 500 ⁇ l of a medium per well of 48-well plates. To the wells, ODF was added at a final concentration of 50 ng/ml. Also, M-CSF was added at a final concentration of 30ng/ml. After three days of incubation, the medium was changed with a fresh one and incubation was carried out for an additional three days to obtain differentiated osteoclasts.
  • RAW264.7 cells differentiated to osteoclasts were obtained as follows. RAW264.7 cells stored at -80 °C were thawed and suspended in an ⁇ -MEM (c-
  • the RAW264.7 cell suspension was transferred to 48-well plates in the density of lxlO 4 cells/500 ⁇ l of medium per well. In the presence of ODF at a concentration of 50 ng/ml, the cells were cultured for 3 days. The medium was changed with a fresh one, followed by culturing for an additional 3 days to obtain differentiated RAW264.7 cells.
  • Western blotting was carried out to determine whether the monoclonal antibody of the present invention specifically recognizes RANK expressed in cells.
  • the expression vector pSRa-RANK-T7 (Kim et al, FEBS Letters 443, 297-302 (1999)) was transfected into human embryonic kidney 293T (HEK293T) cells with the aid of Superfect (Qiagen) added at 2 ⁇ l per ml of the vector.
  • the transfected cells were cultured to overexpress RANK and lysed.
  • the cell lysate was loaded onto an SDS-polyacrylaniide gel (10%) on a vertical electrophoresis apparatus (Bio-Rad) and run at 30 mA.
  • the developed proteins were transferred onto a PVDF film which was then treated with the anti-RANK monoclonal antibody of the present invention as a primary antibody. Thereafter, an HRP (Horse-radish peroxidase, Sigma)-conjugated anti-mouse IgG antibody was used as a secondary antibody.
  • HRP Hase-radish peroxidase, Sigma
  • a RANK protein 90 kDa in size was detected by a chemiluminescent method (Fig. 4), which demonstrates that the monoclonal antibody of the present invention specifically recognizes RANK.
  • EXAMPLE 8 FACS Analysis Using the Anti-RANK Monoclonal Antibody
  • RAW264.7 cells in the same way as in Example 6 were analyzed by FACS.
  • FITC- conjugated BBLl-3(Fab')2 was used as a primary antibody for the FACS analysis.
  • lxlO 6 RAW264.7 cells were put in a microtube and centrifuged. The cells were washed twice with 1.5 ml of an FACS analysis solution (PBS+0.1% BSA+0.1% NaN 3 solution passed through 0.45 ⁇ m filter) and the suspension was centrifuged for 5 min at 1,200 rpm. After removal of the supernatant, the cell pellet was reacted with 50 ⁇ g/ml of the primary antibody conjugated with FITC for 1 hour.
  • the cells were washed twice with 1.5 ml of the FACS analysis solution, followed by centrifuging the suspension at 1 ,200 rpm for 5 min. 500 ⁇ l of 1% paraformaldehyde/PBS (pH 7.3) or the FACS analysis solution was added to suspend the cells and the expression of RANK on cell surface was quantitatively analyzed by use of FACS.
  • the monoclonal antibodies BBL1-1, BBL1-2 and BBL1-3 were applied to osteoclast differentiation model systems.
  • RAW264.7 cells described in Example 6 were dispensed into 48-well plates for tissue culture and induced to differentiation in the presence of RANKL.
  • BBL1-1, BBL1-2 or BBL1-3 was added at a final concentration of 50 ⁇ g/ml.
  • RAW264.7 cells were not treated with any of the antibodies (Non-treated control) or treated with IgGl (Sigma; Mouse IgGl, ⁇ (MOPC31C)) (Isotype control). After three days of incubation, the medium was changed with a fresh one. At this time, RANKL addition and monoclonal antibody treatment were also conducted as described above. After six days of incubation, the medium was removed from the culture plate in which osteoclast had completed differentiation.
  • the cells were immobilized by treatment with a 10% formalin solution for 5 min. After removal of the formalin solution, the cells were treated with 0.1%> Triton X-100 for 10 sec. Then, the cells were dyed with TRAP (tarrrate-resistant acid phosphatase) for 5min in the absence of Triton X-100. Dyeing with TRAP resorted to a leukocyte acid phosphatase kit (Sigma, cat. No. 387- A). After removal of the TRAP dyeing solution, the cells were washed twice with distilled water, dried, and observed with an optical microscope (xlOO) to count TRAP-positive osteoclasts (Fig. 6A).
  • TRAP tarrrate-resistant acid phosphatase
  • Osteoblasts were isolated from one-day-old mice. ICR mice were immersed in 70%) ethanol and the skull was separated by use of scissors and pincettes and cut into several pieces which were then collected in a 6 cm culture plate containing 3x HBSS. They were incubated five times for 15 min at 37 °C in the presence of 0.1% collagcnasc (Gibco BRL) and 0.2% dispase (Boehringer Mannheim). From the second round of the incubation, cell suspensions were gathered, and centrifuged for 5 min at 1,600 rpm to obtain osteoclasts.
  • collagcnasc Gibco BRL
  • dispase Boehringer Mannheim
  • the bone was cut at its opposite ends, and ⁇ -MEM was injected into the bone with a 1ml syringe to completely extract bone marrow cells which were then suspended sufficiently by pipetting several times.
  • Cells myelocytes and red blood cells
  • the pelletized cells were treated for 2 min with about 15-20 ml of ACK buffer (155 mM NH4Cl,llmM KHCO3, 0.01 mM EDTA) and added with phosphate buffer to lyse the red blood cells with caution to minimize damage to the myelocytes. After centrifugation (1600 rpm, 5 min), the cells were suspended in 10% ⁇ -MEM.
  • Osteoblasts and myelocytes were dispensed in 48-well cell culture plates and induced to differentiate in the presence of 1,25-dihydroxy vitamin D3 and prostaglandin E2.
  • BBL1-1, BBL1-2 or BBL1-3 was added to a final concentration of 50 ⁇ g/ml.
  • the cell mixture was not treated with any of the antibodies (Non-treated control) or treated with IgGl (Sigma; Mouse IgGl, ⁇ (MOPC31C)) (Isotype control). After three days of incubation, the medium was changed with a fresh one.
  • Splenocytes (Example 3) and myelocytes (Example 9-2) were dispensed in 48-well cell culture plates and induced to differentiate in the presence of RANKL.
  • BBL1- 1, BBL1-2 and BBL1-3 were added at final concentrations of 50, 10 and 1 ⁇ g/ml, respectively.
  • the cell mixture was not treated with any of the antibodies (Non-treated control) or treated with IgGl (Sigma; Mouse IgGl, ⁇ (MOPC31C)) (Isotype control). After three days of incubation, the medium was changed with a fresh one. At this time, RANKL addition and monoclonal antibody treatment were also conducted as described above.
  • the medium was removed from the culture plates in which osteoclast had completed differentiation.
  • the cells were immobilized by treatment with a 10% formalin solution for 5 min. After removal of the formalin solution, the cells were treated with 0.1% Triton X-100 for 10 sec. Then, the cells were dyed with TRAP (tartrate-resistant acid phosphatase) for 5 min in the absence of Triton X-100. Dyeing with TRAP resorted to a leukocyte acid phosphatase kit (Sigma, cat. No. 387- A). After removal of the TRAP dyeing solution, the cells were washed twice with distilled water, dried, and observed with an optical microscope (xlOO) to count TRAP-positive osteoclasts (Fig. 6C).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des anticorps monoclonaux anti-RANK capables d'inhiber la différenciation des ostéoclastes, un hybridome produisant de tels anticorps, ainsi que des méthodes diagnostiques de maladies des os métaboliques mettant en oeuvre ces anticorps. L'invention concerne également des compositions pharmaceutiques comprenant des anticorps monoclonaux anti-RANK et destinées au traitement de maladies des os métaboliques. Ces anticorps monoclonaux sont également utiles dans le criblage d'inhibiteurs de la différenciation des ostéoclastes.
PCT/KR2003/000553 2002-03-21 2003-03-21 Anticorps monoclonaux anti-rank et compostion pharmaceutique contenant ceux-ci WO2003080671A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003210054A AU2003210054A1 (en) 2002-03-21 2003-03-21 Anti-rank monoclonal antibodies and pharmaceutical composition containing the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2002-0015461 2002-03-21
KR20020015461 2002-03-21

Publications (1)

Publication Number Publication Date
WO2003080671A1 true WO2003080671A1 (fr) 2003-10-02

Family

ID=28450048

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2003/000553 WO2003080671A1 (fr) 2002-03-21 2003-03-21 Anticorps monoclonaux anti-rank et compostion pharmaceutique contenant ceux-ci

Country Status (3)

Country Link
KR (1) KR20030076448A (fr)
AU (1) AU2003210054A1 (fr)
WO (1) WO2003080671A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1544213B1 (fr) * 2003-12-19 2008-02-20 Charité - Universitätsmedizin Berlin Utilisation de ligands de l'antigène CD52 pour le traitement de tumeurs solides et des cancers de type osseux
EP2332992A1 (fr) 2004-03-23 2011-06-15 Biogen Idec MA Inc. Agents de couplage de récepteur et leurs utilisations thérapeutiques
US8900579B2 (en) 2009-10-06 2014-12-02 Alethia Biotherapuetics Inc. Siglec-15 antibodies in treating bone loss-related disease
US9040246B2 (en) 2006-02-13 2015-05-26 Alethia Biotherapeutics Inc. Methods of making antibodies that bind polypeptides involved in the process of bone remodeling
US9493562B2 (en) 2012-07-19 2016-11-15 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
US9757451B2 (en) 2011-11-07 2017-09-12 UNIVERSITé LAVAL Use of RANK/RANKL antagonists for treating muscular dystrophy
WO2020113274A1 (fr) * 2018-12-05 2020-06-11 The Council Of The Queensland Institute Of Medical Research Antagonistes de rank et leurs utilisations

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100911852B1 (ko) * 2007-11-26 2009-08-11 고려대학교 산학협력단 유세포 분석기를 이용한 신규한 ｒａｎｋ와 ｒａｎｋ리간드의 결합 분석방법
KR101627020B1 (ko) 2013-12-02 2016-06-02 충북대학교 산학협력단 적 백혈병 세포에서 발현되는 icama4를 인지하는 항체 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028424A2 (fr) * 1996-12-23 1998-07-02 Immunex Corporation Activateur du recepteur de nf-kappab, recepteur membre de la superfamille des recepteurs de tnf

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028424A2 (fr) * 1996-12-23 1998-07-02 Immunex Corporation Activateur du recepteur de nf-kappab, recepteur membre de la superfamille des recepteurs de tnf

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANDERSON D.M. ET AL.: "A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function", NATURE, vol. 390, 1997, pages 175 - 179, XP002107475, DOI: doi:10.1038/36593 *
HOFBAUER L.C., HEUFELDER A.E.: "Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology", J. MOL. MED., vol. 79, 2001, pages 243 - 253 *
NAKAGAWA N. ET AL.: "RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 253, 1998, pages 395 - 400, XP002956544, DOI: doi:10.1006/bbrc.1998.9788 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1544213B1 (fr) * 2003-12-19 2008-02-20 Charité - Universitätsmedizin Berlin Utilisation de ligands de l'antigène CD52 pour le traitement de tumeurs solides et des cancers de type osseux
EP2332992A1 (fr) 2004-03-23 2011-06-15 Biogen Idec MA Inc. Agents de couplage de récepteur et leurs utilisations thérapeutiques
US9040246B2 (en) 2006-02-13 2015-05-26 Alethia Biotherapeutics Inc. Methods of making antibodies that bind polypeptides involved in the process of bone remodeling
US9067984B2 (en) 2006-02-13 2015-06-30 Alethia Biotherapeutics Inc. Methods of impairing osteoclast differentiation using antibodies that bind Siglec-15
EP1994155B2 (fr) † 2006-02-13 2022-05-04 Daiichi Sankyo Company, Limited Séquences polynucléotidiques et polypeptidiques intervenant dans le processus de remodelage osseux
US9695419B2 (en) 2006-02-13 2017-07-04 Daiichi Sankyo Company, Limited Polynucleotides and polypeptide sequences involved in the process of bone remodeling
US8900579B2 (en) 2009-10-06 2014-12-02 Alethia Biotherapuetics Inc. Siglec-15 antibodies in treating bone loss-related disease
US9388242B2 (en) 2009-10-06 2016-07-12 Alethia Biotherapeutics Inc. Nucleic acids encoding anti-Siglec-15 antibodies
US9617337B2 (en) 2009-10-06 2017-04-11 Daiichi Sankyo Company, Limited Siglec-15 antibodies in treating bone loss-related disease
US9757451B2 (en) 2011-11-07 2017-09-12 UNIVERSITé LAVAL Use of RANK/RANKL antagonists for treating muscular dystrophy
US9493562B2 (en) 2012-07-19 2016-11-15 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
WO2020113274A1 (fr) * 2018-12-05 2020-06-11 The Council Of The Queensland Institute Of Medical Research Antagonistes de rank et leurs utilisations
EP3894441A4 (fr) * 2018-12-05 2022-08-10 The Council of the Queensland Institute of Medical Research Antagonistes de rank et leurs utilisations

Also Published As

Publication number Publication date
KR20030076448A (ko) 2003-09-26
AU2003210054A1 (en) 2003-10-08

Similar Documents

Publication Publication Date Title
KR100895749B1 (ko) Ｎｋｇ２ｄ의 조절
AU738981B2 (en) Methods and compositions for immunomodulation
RU2658603C2 (ru) Антитела против человеческого csf-1r и их применения
CN106749662B (zh) 抗icos的抗体及其用途
CN113039205B (zh) 靶向cll1的抗体及其应用
CN112566698A (zh) T细胞受体和表达该t细胞受体的工程化细胞
JP2004041195A (ja) 新規蛋白質及びその製造方法
JP2003524644A (ja) Ｃｄ４０−結合性ａｐｃ−活性化分子
WO2014022758A1 (fr) Anticorps de liaison double à agent unique anti-pd-l1 et pd-l2 et procédés d'utilisation
CN109384845B (zh) 一种cd40单克隆抗体、其制备方法及其应用
US8021860B2 (en) Method for producing human antibodies to a self physiological receptor by site-directed in vitro immunization of human lymphocytes
EP1767625A1 (fr) Régulateur d'activité pour une cellule produisant de l'interferon
AU733165B2 (en) Method of preparing a monoclonal antibody, monoclonal antibody, a pharmaceutical composition and a diagnostic reagent
WO2003080671A1 (fr) Anticorps monoclonaux anti-rank et compostion pharmaceutique contenant ceux-ci
EP0503646A1 (fr) Anticorps monocloneaux dressés contre l'antigène-3 associé à la fonction lymphocyte
AU2369101A (en) Antibodies against plasma cells
JPH0759588A (ja) 増殖因子レセプターに対するモノクローナル抗体の製造方法及び抗ｃ−ｅｒｂＢ−２モノクローナル抗体
CN118165118A (zh) 靶向axl的嵌合抗原受体及其应用
WO2000020442A1 (fr) Peptides antigenes specifiques aux tumeurs
KR20000016598A (ko) 신규단백질및그제조방법
MXPA99003283A (en) Methods and compositions for immunomodulation
AU2004202566A1 (en) Method for Producing Human Antibodies with Properties of Agonist, Antagonist, or Inverse Agonist

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP